Chronic venous disease encompasses a spectrum of disorders caused by an abnormal venous system. They include chronic venous insufficiency, varicose veins, lipodermatosclerosis, post-thrombotic syndrome, and venous ulceration. Some evidence suggests a genetic predisposition to chronic venous disease due to gene polymorphisms associated mainly with vein wall remodelling. The literature exploring these polymorphisms has not been reviewed and compiled thus far. In this narrative and systematic review, we present the current evidence available on the role of polymorphisms in genes involved in vein wall remodelling and other pathways as contributors to chronic venous disease. We searched the EMBASE, Medline, and PubMed databases from inception to 2013 for basic science or clinical studies relating to genetic associations in chronic venous disease, and obtained 38 relevant studies for this review. Important candidate genes/proteins include the matrix metalloproteinases (extracellular matrix degradation), vascular endothelial growth factors (angiogenesis and vessel wall integrity), FOXC2 (vascular development), HFE (venous ulceration and iron absorption) and various types of collagen (contributors to vein wall strength). The data on associations between these genes/proteins and the post-thrombotic syndrome is limited and additional studies are required. These associations might have future prognostic and therapeutic implications.
Introduction
Chronic venous disease (CVD) refers to a spectrum of overlapping diseases involving abnormalities of the venous system, both structural and functional. Chronic venous insufficiency (CVI) is a term that describes functional abnormalities of the venous system, but is often used to describe the full range of CVD manifestations such as varicose veins, venous ulceration, lipodermatosclerosis (LDS), and post-thrombotic syndrome (PTS) (essentially a secondary form of CVI). 1, 2, 3 Almost a quarter of the adult population in the Western world has some form of CVD, but treatment is often delayed or deferred due to an underestimation of the prevalence and burden of the condition, leading to significant disability. Treatment is multifactorial, and often includes mechanical and/or surgical measures such as compression devices, leg elevation, ablations, and vein stripping.
PTS, a type of CVD, is an important and frequent chronic complication of deep venous thrombosis (DVT) that develops in 20-50% of patients (severe in 5-10%) following DVT despite appropriate anticoagulation. 12 Risk factors include incomplete DVT symptom resolution, proximal or previous ipsilateral DVT, obesity, and increased age. 12 Although the pathophysiology of PTS is not well understood, it involves venous hypertension caused by persistent venous obstruction and/or valvular reflux due to valve destruction, and recent evidence also supports a role for inflammation. 13 Symptoms are similar to CVI and can be debilitating, often including constant or intermittent limb swelling, aching, cramps, or numbness/tingling (improved with rest or recumbency). Treatment involves symptomatic relief using graduated elastic compression stockings or compression devices, leg elevation, or a trial of horse chestnut seed extract as a last resort. 12, 14, 15 Recently, there has been some research into the genetic contributors and risk factors of CVD such as varicose veins and venous ulceration, mainly relating to certain noted polymorphisms in genes associated with vein wall remodelling. In fact, genetic risk factors are already known to affect wound progression and healing, and screening in this regard may aid in the planning of appropriate individualized treatment and prophylaxis. 16 Also, various thrombophilic single Though various candidate genes have been identified as contributors to CVD, the evidence has not previously been compiled and critically reviewed. In this review, we use a systematic approach to explore the current evidence regarding genetic polymorphisms in vein wall structure and healing/remodelling as potential contributors to CVD, including PTS. Understanding these genetic associations may help clarify the underlying pathophysiology, identify patients at risk, and suggest novel therapeutic options.
Methods
In order to identify potential genes associated with CVD, we conducted a broad computerized literature search. We considered for inclusion any studies, either basic or clinical, describing or potentially describing an association between any gene, gene mutation or genetic . We restricted the search to studies published in English. The retrieved references were initially screened for eligibility based on titles by one author and confirmed by another author. A preliminary list of potentially relevant studies was then independently screened by 2 authors based on titles and abstracts and a final list of studies to review in full was generated by consensus. Any studies whose relevance was unclear were reviewed in full.
Quality of the studies was not assessed due to the lack of validated scales for the type of studies included. We did not plan a meta-analysis because we anticipated substantial heterogeneity among
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Results
Search results
The search process is summarized in Figure 1 . The initial search generated 682 results. Initial screen by title alone resulted in 142 potentially relevant studies. The final selection for review in full included 41 studies of which 3 were excluded and 38 articles were included in the final review.
Genetic Polymorphisms and Chronic Venous Disease
Our literature search yielded various candidate genes that have evidence-based associations with a spectrum of CVD including CVI, varicose veins, LDS, venous ulceration, and PTS (Table   1 ). There was significant overlap in that these genes were often associated with more than one CVD manifestation (Figure 2 ), but they are presented here according to their most significant associations with a given subtype. The matrix metalloproteinases are discussed separately, given their consistent strong associations with various forms of CVD.
Varicose Veins
The ECM is a complex and dynamic framework of collagen, proteoglycans, elastin, glycoproteins, and cellular components. Degradation or destruction of the ECM disrupts the homeostasis of the vein (much of which is maintained by the matrix metalloproteinases -discussed later), thereby leading to varicosity. Vein wall weakness is a key player in the pathophysiology of varicose veins, and collagen is an important matrix component that provides strength; however, collagen dysregulation leads to vein wall abnormalities. 4 In varicose veins, the total elastin content is decreased, type I collagen is upregulated, and type III collagen is downregulated. 7, 19 Jin et al.
the COL1A2 (α-2 type I collagen) gene. They found that this polymorphism upregulated COL1A2 expression and produced a 1.6-fold increase in CVI risk, and speculated that genetic variations in this gene alter transcriptional activity, affect mRNA structure, and ultimately allow expressional upregulation. 4 Kowalewski et al. 20 Increased expression of VEGF-A or its receptor R2 leads to increased activation of nitric oxide synthase, which then leads to vessel wall damage mediated by oxygen free radicals, as well as decreased vessel tone that predisposes to venous stasis. 20 VEGF also plays a key role in angiogenesis, so SNPs in the VEGF gene (C936T and -1780 T/C have been described) can be considered risk factors for impaired wound healing and venous ulceration. 22 Chang et al. 6 conducted a study using microarray bioinformatics that systematically explored various genes involved in biological pathways that may contribute to varicosity. The results showed that 32 genes were upregulated and 74 genes were downregulated in varicose veins, most of which were related to apoptosis and angiogenesis. Important examples of upregulated genes included: HSP90, ILK, and TGF-β1. 6 In fact, Saito et al. 23 earlier noted that TGF-β1
stimulates collagen synthesis and alters levels of matrix metalloproteinases (discussed later).
Mutations in the FOXC2 gene have also been associated with varicose veins. FOXC2
encodes a transcription factor involved in lymphatic and vascular development, and mutations in FOXC2 are seen in lymphoedema distichiasis, which is characterized by lymphoedema and varicose veins. 7, 24 Ng et al. 24 conducted an early twin linkage study that strongly implicated FOXC2 in the development of varicose veins as a heritable condition. Similarly, knowing that
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From FOXC2 had previously been implicated in primary venous valve failure, Al-Batayneh et al. 25 identified three specific SNPs in the FOXC2 gene that may contribute to varicose vein and hemorrhoid development. More recently, Mellor et al. 26 conducted a small study of 18 patients and noted a strong association between FOXC2 and primary venous valve failure in both superficial and deep veins of the lower limb.
Other lesser known genes have also been examined in preliminary studies, and must be mentioned. Jeong et al. 27 performed large scale mRNA screens among normal varicose veins, and found the greatest differential expression in the octamer-binding transcription factor-1 gene (Oct-1), which was upregulated in primary varicose veins. Cario-Toumaniantz et al. 8 found overexpressed vitamin-K dependent matrix gla protein (MGP) in varicose veins, and speculated that its role in wall remodelling involved smooth muscle proliferation and mineralization processes.
Venous Ulceration
Grzela et al. 22 reviewed 4 genes that may play a role in venous ulceration: TNF, FGF-R, estrogen receptor, and HFE. Levels of TNFα and interleukin-1 are higher in venous leg ulcers as compared to normal acute wounds, with certain SNPs (such as the -308A variant in TNFα)
conferring a higher risk of venous ulceration compared to wild-type. 5, 22, 28 Along with demonstrating the above-mentioned association with TNFα, Wallace et al. 28 also identified a polymorphism in intron 10 of the BAT1 gene (HLA-B-associated transcript-1) as being a significant risk factor for venous ulceration.
Similarly, fibroblast growth factors (FGF) and their receptors (FGF-R) are cytokines that are imperative for the control of connective tissue regeneration in wound healing. Kowalewski et al. 9 found increased acidic fibroblast growth factor (a-FGF) expression in the walls of varicose veins. They noted that these walls contained extensive ECM remodelling and altered collagen and glycosaminoglycan differentiation; a-FGF likely influences the expression of certain enzymes
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Furthermore, a-FGF synthesis is enhanced by hypoxia, which may be a consequence of venous stasis. 9 Previous studies indicate that certain SNPs in fibroblast growth factor-receptor type 2 (FGF-R2), most frequently the polymorphism A2451G, are more commonly observed in CVI or ulceration. Though the mechanism is unclear, these SNPs likely result in lower expression of FGF-R2, causing impaired regeneration of connective tissue, longer vein wall re-epithelialization, and eventually CVI or ulceration. 22 Nagy et al. 29 conducted an association study and identified a SNP in the FGF-R2 gene that was more prevalent CVI patients with non-healing ulcers; as mentioned above, this likely led to abnormal re-epithelialization and angiogenesis.
Estrogen is a known contributor to ECM metabolism; in fact, hormone replacement therapy prevents CVI and topical estrogen promotes wound healing in the elderly by decreasing the inflammatory response. 30 Though convincing associations have not been elucidated, several SNPs in the ER-β receptor have been associated with venous ulcers in the elderly. 22, 30 Ashworth et al.
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found that polymorphisms in the upstream regulatory regions of the ER-β gene were significantly associated with venous ulceration, but did not conduct further functional studies to determine the precise mechanism.
Hemochromatosis is an inherited iron overload disease caused by mutations in the HFE gene (most commonly allele C282Y), an MHC class 1-type membrane protein associated with ß2-microglobulin. The mutated gene results in abnormalities in the regulation of iron absorption related to interactions between transferrin and its receptor. In patients with CVI, the HFE C282Y allele increases the risk of ulceration by almost 7-fold, likely due to accumulation of iron in tissues surrounding blood vessels, increased free radicals and oxidative stress, and upregulation of the inflammatory response which finally leads to tissue destruction. 22 Moreover, Gemmati et al.
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found that the -8CG polymorphism in the FPN1 gene (ferroportin; involved in exporting iron out of the cell) increases susceptibility to leg ulcers. Furthermore, imbalances in the matrix metalloproteinases and their inhibitors (discussed later)
have also been implicated in LDS through the generation of epidermal and dermal skin defects.
34
Post-Thrombotic Syndrome
PTS is a frequent yet poorly understood complication of DVT. Previous studies have explored genes involved in vein wall remodelling in relation to CVI and its manifestations (ex.
varicose veins and venous ulcers). These are also manifestations of PTS, and it is logical to infer that polymorphisms in these very genes may potentially increase the risk of PTS as well. In fact, Deatrick et al. 35 noted ongoing vein wall remodelling 6 months after an acute DVT that was associated with biomarkers such as MMP-9 that directly correlate with resolution and predict PTS.
There is, however, a dearth of literature that directly associates the above genes with PTS. 
MMP-9 modulates vein wall collagen content and contributes to inflammation and fibrosis, thus implicating it as a potential target to reduce the fibrotic complications of PTS.
To our knowledge, there has been no study to date that has analyzed polymorphisms in the above-mentioned candidate genes to uncover a direct association with PTS. Some of the studies presented in Table 1 involve tissue blocks from veins complicated by thrombophlebitis, and some of the patients were noted to have a history of venous thrombosis (however, scant patient data was provided), but none of the studies specifically included PTS as a subset.
The Matrix Metalloproteinases
Perhaps the most studied genes in venous disease are the matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMP). A systematic review by Lim et al. Though the molecular mechanisms of these genetic anomalies have not been fully elucidated, it appears that MMPs regulate or degrade the ECM through hydrolysis, while TIMPs are tissue inhibitors of MMPs that influence vascular remodelling. Hence, an imbalance between these proteins may lead to abnormalities in the vessel wall and, ultimately, vascular disease such as varicosity and ulceration. 7, 35, 40 Moreover, misregulation of MMP activity and TIMP counterregulation contributes to impaired ulcer healing. 34 An early study by Saito et al. 23 suggested that increased MMP-2 levels affect tissue remodelling and contribute to a pro-ulcer environment.
Subsequently, Herouy et al. 41 examined stasis dermatitis, a common consequence of impaired venous drainage characterized by dermal neovascularization, and noted elevated MMP-1, -2, -13
and diminished TIMP-1, -2 in the skin lesions. More recently, Xu et al. 40 showed that specific did not predict susceptibility to varicose veins, but this study likely did not have the power to uncover the milder effects of these genes on an otherwise multifactorial disorder.
Discussion
In this review, we examined different candidate genes and their polymorphisms (mostly SNPs) that have been linked to various forms of CVD.
In assessing the above studies, a few candidate genes should be highlighted as having the strongest link to the development of CVD (as we could not perform a meta-analysis, these assessments are qualitative, based on the available evidence). Three studies agree that SNPs in FOXC2, a transcription factor involved in lymphatic and vascular development, provide a strong link toward venous varicosity, valve failure, and hemorrhoids. On the other hand, a polymorphism in the HFE gene increases the risk of venous ulceration by almost 7-fold, while also causing the known dysregulation in iron absorption. The MMPs (and, to a lesser extent, their inhibitorsTIMPs) are perhaps the best studied in venous disease.
MMPs are involved in ECM degradation
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Although genetic markers in CVD have been examined in some detail, there is a lack of evidence correlating these genes with the development and severity of PTS. If these polymorphisms are potentially associated with CVI, LDS, varicose veins, venous ulcers, and DVT resolution, it is plausible that they could also provide an underlying substrate for the development of PTS. The MMPs have once again been implicated in this respect, but data is scarce and further research is warranted.
In general, a limitation of all of the studies included in this review relates to the fact that they were conducted either in animal models, in very limited numbers of patients, or using surgical samples (e.g. saphenectomy). It is very difficult to assess the quality of each study since no standardized tools exist in this regard, in contrast to the quality assessment scales used for clinical studies. We believe that the included studies were methodologically sound; however, we cannot totally rule out the possibility of biased results.
Clearly, the genetic predisposition to CVD, particularly PTS, is controversial and unclear at best, and more studies are needed to clarify these associations. Earlier studies have promoted the use of a genome-wide approach; this allows for the identification of previously unknown markers, and may be a consideration for the future. Clinically, this would be a novel way to re-examine a patient's propensity toward developing CVD, predict those who go on to develop it, and provide a better understanding of the underlying mechanisms to ultimately improve treatment options.
Conclusions
Herein, we examine the role of various candidate genes and their polymorphisms in the development of CVD, including the lesser studied PTS. Our observations support a genetic For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From predisposition to CVD related to vein wall remodelling. Genes of significance include FOXC2, HFE, and the MMPs, all of which show strong associations with varicose veins, CVI, or venous ulceration. The data surrounding PTS is more limited, but given that it is a type of CVD with similar manifestations, we may infer that some of the above genes may be implicated. Thus, further studies are needed to examine these associations more directly. Most importantly, given the burden of this disease worldwide and the paucity of treatment options currently available, studying these polymorphisms could potentially allow us to better identify patients at higher risk of developing CVD, and also provide novel therapeutic targets. 
